Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsConstruction in ProgressCurrent AssetsCurrent Deferred Tax AssetsCurrent Deferred Tax AssetsCurrent TaxesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dr Reddys Laboratories (RDY) Current Assets (2017 - 2026)

Dr Reddys Laboratories has reported Current Assets over the past 10 years, most recently at $3.3 billion for Q1 2026.

  • For Q1 2026, Current Assets rose 14.37% year-over-year to $3.3 billion; the TTM value through Mar 2026 reached $3.3 billion, up 14.37%, while the annual FY2026 figure was $3.3 billion, 12.82% up from the prior year.
  • Current Assets for Q1 2026 was $3.3 billion at Dr Reddys Laboratories, up from $2.9 billion in the prior quarter.
  • Over five years, Current Assets peaked at $3.3 billion in Q1 2026 and troughed at $84.8 million in Q1 2023.
  • A 5-year average of $1.9 billion and a median of $2.9 billion in 2025 define the central range for Current Assets.
  • Biggest five-year swings in Current Assets: fell 16.39% in 2022 and later surged 3421.73% in 2024.
  • Year by year, Current Assets stood at $100.7 million in 2022, then dropped by 15.74% to $84.8 million in 2023, then soared by 3421.73% to $3.0 billion in 2024, then dropped by 3.3% to $2.9 billion in 2025, then increased by 14.37% to $3.3 billion in 2026.
  • Business Quant data shows Current Assets for RDY at $3.3 billion in Q1 2026, $2.9 billion in Q1 2025, and $3.0 billion in Q1 2024.